2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Study Population, Human, Adult, Animal Model
PAPER

4082 Selective retention of Hoxb5⁺ long-term hematopoietic stem cells during hematopoietic mobilization

Ruby Honjol, Allison Banuelos, PhD2, Irving Weissman, MD3
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
Long-term hematopoietic stem cells (LT-HSCs) sustain lifelong hematopoiesis through self-renewal and are responsible for durable hematopoietic reconstitution following transplantation. Although hematopoietic stem cells can be detected in peripheral blood, they comprise less than 0.01% of circulating nucleated cells, and whether these rare circulating HSCs represent bona fide LT-HSCs remains unknown. We previously identified Hoxb5 as a highly specific marker of LT-HSCs, enabling their prospective isolation and in vivo tracking. Here, we investigated the fate of Hoxb5⁺ LT-HSCs during physiological homeostasis and clinically relevant hematopoietic stem cell mobilization.

Using Hoxb5-mCherry reporter mice, HSC mobilization was induced with cyclophosphamide followed by two daily doses of G-CSF. Despite robust mobilization of phenotypic HSCs, the vast majority of Hoxb5⁺ LT-HSCs remained within the bone marrow, with only a small fraction detected in the spleen, liver, and peripheral blood. Accordingly, the frequency of Hoxb5⁺ LT-HSCs within the bone marrow remained largely unchanged following mobilization. Notably, fewer than 10% of phenotypic HSCs recovered from mobilized peripheral blood expressed Hoxb5, demonstrating that the circulating HSC compartment is composed predominantly of Hoxb5⁻ cells.

To determine whether retained LT-HSCs underwent differentiation during mobilization, Hoxb5-CreER;Rosa26-ZsGreen lineage-tracing mice were analyzed following CY/G-CSF treatment. The vast majority of labeled Hoxb5⁺ LT-HSCs retained their identity, with minimal contribution to Hoxb5⁻ HSCs, short-term HSCs, or downstream progenitors. Consistent with limited differentiation, fewer than 1% of circulating ZsGreen⁺ cells were detected in peripheral blood and were composed predominantly of mature CD11b⁺ myeloid cells.

To determine whether limited trafficking is an intrinsic property of Hoxb5⁺ LT-HSCs, steady-state parabiosis was performed using Hoxb5-mCherry reporter mice. Despite complete equilibration of circulating blood cells between parabionts, Hoxb5⁺ LT-HSCs failed to equilibrate between partners, demonstrating minimal physiological trafficking between bone marrow niches. Finally, Hoxb5-mCherry⁺ and Hoxb5-mCherry⁻ HSCs isolated following mobilization were transplanted into lethally irradiated CD45.1 recipients. Hoxb5-mCherry⁺ LT-HSCs retained robust long-term multilineage reconstitution, whereas Hoxb5-mCherry⁻ HSCs exhibited minimal durable engraftment.

Together, these findings reveal that bona fide Hoxb5⁺ LT-HSCs are selectively retained within the bone marrow, resisting both physiological trafficking and pharmacologic mobilization while preserving robust long-term regenerative capacity. In contrast, the majority of HSCs recovered from mobilized peripheral blood are Hoxb5⁻ and exhibit limited durable engraftment, demonstrating that the mobilized HSC compartment is compositionally and functionally distinct from the bona fide LT-HSC population retained within the bone marrow. These findings challenge the longstanding assumption that mobilized peripheral blood HSCs faithfully represent the long-term regenerative stem cell compartment and raise the fundamental question of what mechanisms selectively retain the most potent self-renewing HSCs within their native niche. Defining these mechanisms may inform the development of next-generation mobilization strategies that more effectively recruit LT-HSCs for hematopoietic stem cell transplantation.
Allison Banuelos, PhD: No relevant conflicts of interest to declare.